Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: An edge router for interfacing an optical label switched core IP network with client networks, which may be electronically switched and operate with different protocol. The core network has a limited number of ports, each with an edge router, which receives packets from one or more associated client networks and queues them according to egress port on the core network and optionally additionally according to attribute of service. When a queue has exceed a maximum packet length or a timeout limit assigned to the queue, the packets including their headers are assembled into a super packet for transmission across the core network in optical form, preferably using optical routers incorporating wavelength conversion of payloads and switching according to an attached label. The edge router at the egress port disassembles the super packet into constituent packets for respective destinations on the client network.

Abstract: An edge router for interfacing an optical label switched core IP network with client networks, which may be electronically switched and operate with different protocol. The core network has a limited number of ports, each with an edge router, which receives packets from one or more associated client networks and queues them according to egress port on the core network and optionally additionally according to attribute of service. When a queue has exceed a maximum packet length or a timeout limit assigned to the queue, the packets including their headers are assembled into a super packet for transmission across the core network in optical form, preferably using optical routers incorporating wavelength conversion of payloads and switching according to an attached label. The edge router at the egress port disassembles the super packet into constituent packets for respective destinations on the client network.

Abstract: An edge router for interfacing an optical label switched core IP network with client networks, which may be electronically switched and operate with different protocol. The core network has a limited number of ports, each with an edge router, which receives packets from one or more associated client networks and queues them according to egress port on the core network and optionally additionally according to attribute of service. When a queue has exceed a maximum packet length or a timeout limit assigned to the queue, the packets including their headers are assembled into a super packet for transmission across the core network in optical form, preferably using optical routers incorporating wavelength conversion of payloads and switching according to an attached label. The edge router at the egress port disassembles the super packet into constituent packets for respective destinations on the client network.

Abstract: An edge router for interfacing an optical label switched core IP network with client networks, which may be electronically switched and operate with different protocol. The core network has a limited number of ports, each with an edge router, which receives packets from one or more associated client networks and queues them according to egress port on the core network and optionally additionally according to attribute of service. When a queue has exceed a maximum packet length or a timeout limit assigned to the queue, the packets including their headers are assembled into a super packet for transmission across the core network in optical form, preferably using optical routers incorporating wavelength conversion of payloads and switching according to an attached label. The edge router at the egress port disassembles the super packet into constituent packets for respective destinations on the client network.

Abstract: A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Abstract: An adherent article, such as a bandage or adhesive tape, having a nonwoven substrate that contains water soluble fibers is provided. The water soluble fibers of the nonwoven substrate can include polyvinyl alcohol fibers that only dissolve at temperatures greater than 37° C. and/or polyvinyl alcohol fibers that can dissolve at temperatures less than about 37° C. The adherent article also includes a pressure-sensitive adhesive applied to the nonwoven substrate that facilitates adherence of the substrate to human skin. The pressure-sensitive adhesive can be water soluble or generally insoluble, but dispersible in water.